280 related articles for article (PubMed ID: 21936830)
1. SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions.
Zani ML; Tanga A; Saidi A; Serrano H; Dallet-Choisy S; Baranger K; Moreau T
Biochem Soc Trans; 2011 Oct; 39(5):1441-6. PubMed ID: 21936830
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family.
Moreau T; Baranger K; Dadé S; Dallet-Choisy S; Guyot N; Zani ML
Biochimie; 2008 Feb; 90(2):284-95. PubMed ID: 17964057
[TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.
Zani ML; Baranger K; Guyot N; Dallet-Choisy S; Moreau T
Protein Sci; 2009 Mar; 18(3):579-94. PubMed ID: 19241385
[TBL] [Abstract][Full Text] [Related]
4. Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate.
Baranger K; Zani ML; Labas V; Dallet-Choisy S; Moreau T
PLoS One; 2011; 6(6):e20976. PubMed ID: 21687692
[TBL] [Abstract][Full Text] [Related]
5. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase.
Guyot N; Zani ML; Maurel MC; Dallet-Choisy S; Moreau T
Biochemistry; 2005 Nov; 44(47):15610-8. PubMed ID: 16300411
[TBL] [Abstract][Full Text] [Related]
6. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function.
Baranger K; Zani ML; Chandenier J; Dallet-Choisy S; Moreau T
FEBS J; 2008 May; 275(9):2008-20. PubMed ID: 18341586
[TBL] [Abstract][Full Text] [Related]
7. Protection of lung epithelial cells from protease-mediated injury by trappin-2 A62L, an engineered inhibitor of neutrophil serine proteases.
Tanga A; Saidi A; Jourdan ML; Dallet-Choisy S; Zani ML; Moreau T
Biochem Pharmacol; 2012 Jun; 83(12):1663-73. PubMed ID: 22465040
[TBL] [Abstract][Full Text] [Related]
8. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase.
van Wetering S; van der Linden AC; van Sterkenburg MA; Rabe KF; Schalkwijk J; Hiemstra PS
J Investig Med; 2000 Sep; 48(5):359-66. PubMed ID: 10979241
[TBL] [Abstract][Full Text] [Related]
9. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease.
Schmid M; Fellermann K; Fritz P; Wiedow O; Stange EF; Wehkamp J
J Leukoc Biol; 2007 Apr; 81(4):907-15. PubMed ID: 17200145
[TBL] [Abstract][Full Text] [Related]
10. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes.
Sallenave JM; Shulmann J; Crossley J; Jordana M; Gauldie J
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):733-41. PubMed ID: 7946401
[TBL] [Abstract][Full Text] [Related]
11. Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid.
Laugisch O; Schacht M; Guentsch A; Kantyka T; Sroka A; Stennicke HR; Pfister W; Sculean A; Potempa J; Eick S
Mol Oral Microbiol; 2012 Feb; 27(1):45-56. PubMed ID: 22230465
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris.
Zani ML; Nobar SM; Lacour SA; Lemoine S; Boudier C; Bieth JG; Moreau T
Eur J Biochem; 2004 Jun; 271(12):2370-8. PubMed ID: 15182352
[TBL] [Abstract][Full Text] [Related]
13. SLPI and elafin: multifunctional antiproteases of the WFDC family.
Scott A; Weldon S; Taggart CC
Biochem Soc Trans; 2011 Oct; 39(5):1437-40. PubMed ID: 21936829
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of human elafin.
Shaw L; Wiedow O
Biochem Soc Trans; 2011 Oct; 39(5):1450-4. PubMed ID: 21936832
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin.
Guyot N; Zani ML; Berger P; Dallet-Choisy S; Moreau T
Biol Chem; 2005 Apr; 386(4):391-9. PubMed ID: 15899702
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor.
Wright CD; Kennedy JA; Zitnik RJ; Kashem MA
Biochem Biophys Res Commun; 1999 Jan; 254(3):614-7. PubMed ID: 9920787
[TBL] [Abstract][Full Text] [Related]
17. Interaction of secretory leukocyte protease inhibitor with proteinase-3.
Rao NV; Marshall BC; Gray BH; Hoidal JR
Am J Respir Cell Mol Biol; 1993 Jun; 8(6):612-6. PubMed ID: 8100709
[TBL] [Abstract][Full Text] [Related]
18. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma.
Wright CD; Havill AM; Middleton SC; Kashem MA; Lee PA; Dripps DJ; O'Riordan TG; Bevilacqua MP; Abraham WM
J Pharmacol Exp Ther; 1999 May; 289(2):1007-14. PubMed ID: 10215681
[TBL] [Abstract][Full Text] [Related]
19. Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3.
Nobar SM; Zani ML; Boudier C; Moreau T; Bieth JG
FEBS J; 2005 Nov; 272(22):5883-93. PubMed ID: 16279952
[TBL] [Abstract][Full Text] [Related]
20. Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung.
Tremblay GM; Sallenave JM; Israél-Assayag E; Cormier Y; Gauldie J
Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):1092-8. PubMed ID: 8887613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
